Clinical data support their ability to reduce risks of heart failure (30), atherosclerosis (31), and hypertension (32), highlighting their potential as systemic therapeutics
CMS Issues Coverage Guidance on GLP-1 Anti-Obesity Drugs: Implications for Health Plans Posted on April 5, 2024 CMS Issued Coverage Guidance on GLP-1 Anti-Obesity Drugs Requiring Considerations for Health Plans GLP-1s (glucagon-like peptide 1 agonist) came up in the news again after the Centers for Medicare and Medicaid Services (CMS) issued coverage guidance on GLP-1 anti-obesity drugs with expanded indications on March 20, 2024.* Since the inception of Medicare Part D, drugs used for weight loss have been excluded from basic coverage
Unfortunately, in our case no previous pure-tone audiometry tests were performed, which makes it impossible to determine whether the hearing loss is progressive or whether it has remained at the same level since the end of chemotherapy
Accordingly, we evaluated the effects of long-term HFD consumption on Grx expression by western blot
The FDA has also warned that SARMs can have serious side effects including an increased risk of stroke [27]
Key benefits include: Significant Weight Reduction: Clinical studies show that patients taking Semaglutide often lose more weight than those relying solely on traditional diet and exercise
